Short answer
Tenaya Therapeutics Inc (TNYA) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Alnylam upfront payment up to $10M (subject to $500K reductions per underperforming target, max 8 targets).
Tenaya Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Alnylam upfront payment up to $10M (subject to $500K reductions per underperforming target, max 8 targets)
- Total milestone potential up to $1.13B in development, regulatory, and sales-based payments for Company-nominated targets
- 24-month research collaboration on 15 cardiovascular gene targets; Alnylam funds TNYA's FTE and out-of-pocket costs per agreed budget
- Alnylam gets exclusive worldwide license with sublicense rights; TNYA restricted from independent R&D on collaboration targets during term
- Alnylam holds unilateral termination right for any reason; if NHP pharmacodynamic study not commenced within evaluation window, target license reverts to TNYA
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tenaya Therapeutics Inc 8-K filings
Get the next TNYA 8-K as it lands
Follow TNYA for push alerts, or ask the research agent what this filing means.